Resurfacing a December 2024 move: Novo Nordisk India pushed for earlier Wegovy launch as Lilly prepared Mounjaro entry
Resurfacing news from December 2024, Novo Nordisk's India team sought to bring forward Wegovy's expected 2026 debut as Eli Lilly targeted a 2025 launch for Mounjaro. The race could reshape India's premium obesity-drug market before lower-cost semaglutide rivals emerge.
The brand move
Novo Nordisk India is pushing to advance Wegovy from a potential 2026 launch as Eli Lilly targets a 2025 Mounjaro introduction. The companies are scaling supply while Indian drugmakers prepare cheaper semaglutide alternatives subject to patent expiry.
The numbers
- 2026
- 2025
- two months
- $150 billion
- late 2022
Why it matters for the brand
India’s premium pharmacy and healthcare retailers should prepare for GLP-1 demand by securing cold-chain capacity, clinician partnerships, and patient-support services ahead of Wegovy and Mounjaro launches.
The counter-case
The headline may overstate how quickly a premium obesity-drug race can translate into meaningful Indian sales. Wegovy and Mounjaro face a narrow self-pay market, high monthly treatment costs, limited reimbursement, uneven specialist capacity, and potential supply constraints. An earlier launch would not necessarily offset Lilly’s advantage if Mounjaro is priced more aggressively, has stronger availability, or gains faster physician adoption. Moreover, lower-cost semaglutide competition could matter only after regulatory, patent, and manufacturing hurdles are cleared, so it is premature to frame it as an imminent market reset.